Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.17
NYSE:Q's Cash-to-Debt is ranked lower than
88% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. NYSE:Q: 0.17 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:Q' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 0.38 Max: N/A
Current: 0.17
Equity-to-Asset 0.41
NYSE:Q's Equity-to-Asset is ranked lower than
72% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NYSE:Q: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:Q' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.54  Med: -0.22 Max: 0.41
Current: 0.41
-0.54
0.41
Interest Coverage 4.46
NYSE:Q's Interest Coverage is ranked lower than
82% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.15 vs. NYSE:Q: 4.46 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:Q' s Interest Coverage Range Over the Past 10 Years
Min: 2.79  Med: 3.74 Max: 6.4
Current: 4.46
2.79
6.4
Piotroski F-Score: 5
Altman Z-Score: 1.30
Beneish M-Score: -1.30
WACC vs ROIC
6.70%
-2.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 9.33
NYSE:Q's Operating Margin % is ranked higher than
67% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. NYSE:Q: 9.33 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:Q' s Operating Margin % Range Over the Past 10 Years
Min: 7.98  Med: 9.33 Max: 11.26
Current: 9.33
7.98
11.26
Net Margin % 1.67
NYSE:Q's Net Margin % is ranked higher than
54% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.05 vs. NYSE:Q: 1.67 )
Ranked among companies with meaningful Net Margin % only.
NYSE:Q' s Net Margin % Range Over the Past 10 Years
Min: 1.67  Med: 4.44 Max: 6.75
Current: 1.67
1.67
6.75
ROE % 8.38
NYSE:Q's ROE % is ranked higher than
63% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.21 vs. NYSE:Q: 8.38 )
Ranked among companies with meaningful ROE % only.
NYSE:Q' s ROE % Range Over the Past 10 Years
Min: 2.85  Med: 2.85 Max: 8.38
Current: 8.38
2.85
8.38
ROA % 1.55
NYSE:Q's ROA % is ranked higher than
59% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. NYSE:Q: 1.55 )
Ranked among companies with meaningful ROA % only.
NYSE:Q' s ROA % Range Over the Past 10 Years
Min: 0.92  Med: 9.43 Max: 20.82
Current: 1.55
0.92
20.82
ROC (Joel Greenblatt) % 269.27
NYSE:Q's ROC (Joel Greenblatt) % is ranked higher than
98% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. NYSE:Q: 269.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:Q' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 209.76  Med: 267.89 Max: 338.36
Current: 269.27
209.76
338.36
3-Year Revenue Growth Rate 4.30
NYSE:Q's 3-Year Revenue Growth Rate is ranked higher than
52% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. NYSE:Q: 4.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:Q' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 3.4  Med: 4.3 Max: 6.2
Current: 4.3
3.4
6.2
3-Year EBITDA Growth Rate 11.50
NYSE:Q's 3-Year EBITDA Growth Rate is ranked higher than
67% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. NYSE:Q: 11.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:Q' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 2.4  Med: 12.2 Max: 19
Current: 11.5
2.4
19
3-Year EPS without NRI Growth Rate -24.60
NYSE:Q's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. NYSE:Q: -24.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:Q' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -24.6  Med: 9.55 Max: 26.8
Current: -24.6
-24.6
26.8
GuruFocus has detected 4 Warning Signs with Quintiles IMS Holdings Inc $NYSE:Q.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:Q's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

Q Guru Trades in Q1 2016

Columbia Wanger 1,375,000 sh (New)
Jim Simons 660,100 sh (+276.98%)
Joel Greenblatt 224,517 sh (+191.89%)
Ron Baron 516,806 sh (+1.82%)
John Hussman Sold Out
Ken Fisher 54,064 sh (-0.20%)
Paul Tudor Jones 23,076 sh (-19.56%)
Vanguard Health Care Fund 1,932,338 sh (-59.53%)
» More
Q2 2016

Q Guru Trades in Q2 2016

John Paulson 164,200 sh (New)
Larry Robbins 1,919,555 sh (New)
Ken Fisher 88,164 sh (+63.07%)
Paul Tudor Jones 37,446 sh (+62.27%)
Joel Greenblatt 350,600 sh (+56.16%)
Vanguard Health Care Fund 2,929,638 sh (+51.61%)
Jim Simons 528,700 sh (-19.91%)
Columbia Wanger 1,010,406 sh (-26.52%)
Ron Baron 371,210 sh (-28.17%)
» More
Q3 2016

Q Guru Trades in Q3 2016

Larry Robbins 3,381,622 sh (+76.17%)
Ken Fisher 126,587 sh (+43.58%)
John Paulson Sold Out
Vanguard Health Care Fund 2,539,738 sh (-13.31%)
Columbia Wanger 836,973 sh (-17.16%)
Ron Baron 300,810 sh (-18.97%)
Joel Greenblatt 241,654 sh (-31.07%)
Jim Simons 242,300 sh (-54.17%)
Paul Tudor Jones 16,149 sh (-56.87%)
» More
Q4 2016

Q Guru Trades in Q4 2016

Larry Robbins 6,927,335 sh (+104.85%)
Vanguard Health Care Fund 4,338,077 sh (+70.81%)
Joel Greenblatt 294,178 sh (+21.74%)
Ken Fisher 134,287 sh (+6.08%)
Jim Simons Sold Out
Paul Tudor Jones 11,600 sh (-28.17%)
Ron Baron 134,776 sh (-55.20%)
Columbia Wanger 268,642 sh (-67.90%)
» More
» Details

Insider Trades

Latest Guru Trades with Q

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621399    SIC: 8099
Compare:NYSE:A, NYSE:LH, NYSE:DGX, NAS:IDXX, OTCPK:SSMXY, OTCPK:ERFSF, NAS:DXCM, NAS:QGEN, OTCPK:BMXMF, NYSE:PKI, NYSE:BIO.B, NAS:ICLR, NYSE:CRL, NAS:BRKR, NAS:PRAH, NYSE:ALR, OTCPK:CZMWY, NAS:PRXL, NAS:NEOG, NAS:EXAS » details
Traded in other countries:QTS.Germany,
Quintiles Transnational Holdings Inc provides biopharmaceutical development services and commercial outsourcing services. Its two operating segments are Product Development segment and Integrated Healthcare Services segment.

Quintiles IMS Holdings Inc, formerly known as Quintiles Transnational Holdings Inc was founded in February 1982. The Company completed its initial public offering on May 9, 2013. It is an information and technology company. The Company offers professional services, information technology and partnering solutions to the pharmaceutical services, biotechnology and healthcare industries.

Ratios

vs
industry
vs
history
PE Ratio 106.36
Q's PE Ratio is ranked lower than
95% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. Q: 106.36 )
Ranked among companies with meaningful PE Ratio only.
Q' s PE Ratio Range Over the Past 10 Years
Min: 18.67  Med: 24.06 Max: 108.99
Current: 106.36
18.67
108.99
Forward PE Ratio 17.33
Q's Forward PE Ratio is ranked higher than
81% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.08 vs. Q: 17.33 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 106.36
Q's PE Ratio without NRI is ranked lower than
95% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.37 vs. Q: 106.36 )
Ranked among companies with meaningful PE Ratio without NRI only.
Q' s PE Ratio without NRI Range Over the Past 10 Years
Min: 18.67  Med: 24.06 Max: 108.99
Current: 106.36
18.67
108.99
Price-to-Owner-Earnings 22.10
Q's Price-to-Owner-Earnings is ranked higher than
67% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.26 vs. Q: 22.10 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Q' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.39  Med: 20.25 Max: 22.65
Current: 22.1
15.39
22.65
PB Ratio 2.23
Q's PB Ratio is ranked higher than
69% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.51 vs. Q: 2.23 )
Ranked among companies with meaningful PB Ratio only.
Q' s PB Ratio Range Over the Past 10 Years
Min: 2.13  Med: 2.22 Max: 2.29
Current: 2.23
2.13
2.29
PS Ratio 1.47
Q's PS Ratio is ranked higher than
77% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. Q: 1.47 )
Ranked among companies with meaningful PS Ratio only.
Q' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.41 Max: 1.77
Current: 1.47
1.02
1.77
Price-to-Free-Cash-Flow 15.11
Q's Price-to-Free-Cash-Flow is ranked higher than
77% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.89 vs. Q: 15.11 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Q' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.21  Med: 20.95 Max: 35.19
Current: 15.11
14.21
35.19
Price-to-Operating-Cash-Flow 12.23
Q's Price-to-Operating-Cash-Flow is ranked higher than
72% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.95 vs. Q: 12.23 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Q' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.67  Med: 16.75 Max: 26.43
Current: 12.23
11.67
26.43
EV-to-EBIT 39.31
Q's EV-to-EBIT is ranked lower than
83% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.75 vs. Q: 39.31 )
Ranked among companies with meaningful EV-to-EBIT only.
Q' s EV-to-EBIT Range Over the Past 10 Years
Min: 13.8  Med: 16.4 Max: 39.31
Current: 39.31
13.8
39.31
EV-to-EBITDA 26.85
Q's EV-to-EBITDA is ranked lower than
84% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.68 vs. Q: 26.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
Q' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.5  Med: 13.6 Max: 26.85
Current: 26.85
11.5
26.85
PEG Ratio 8.00
Q's PEG Ratio is ranked lower than
85% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.09 vs. Q: 8.00 )
Ranked among companies with meaningful PEG Ratio only.
Q' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 8.05
Current: 8
0
8.05
Current Ratio 1.23
Q's Current Ratio is ranked lower than
82% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.70 vs. Q: 1.23 )
Ranked among companies with meaningful Current Ratio only.
Q' s Current Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.27 Max: 1.51
Current: 1.23
1.15
1.51
Quick Ratio 1.23
Q's Quick Ratio is ranked lower than
77% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. Q: 1.23 )
Ranked among companies with meaningful Quick Ratio only.
Q' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.27 Max: 1.51
Current: 1.23
1.15
1.51
Days Sales Outstanding 52.96
Q's Days Sales Outstanding is ranked higher than
64% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. Q: 52.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
Q' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.13  Med: 29.51 Max: 52.96
Current: 52.96
25.13
52.96
Days Payable 19.21
Q's Days Payable is ranked lower than
88% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.14 vs. Q: 19.21 )
Ranked among companies with meaningful Days Payable only.
Q' s Days Payable Range Over the Past 10 Years
Min: 8.02  Med: 9.9 Max: 19.21
Current: 19.21
8.02
19.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -24.20
Q's 3-Year Average Share Buyback Ratio is ranked lower than
76% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. Q: -24.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
Q' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.2  Med: -2.45 Max: -0.4
Current: -24.2
-24.2
-0.4

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.04
Q's Price-to-Median-PS-Value is ranked higher than
52% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. Q: 1.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Q' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.81  Med: 1.02 Max: 1.07
Current: 1.04
0.81
1.07
Earnings Yield (Greenblatt) % 2.50
Q's Earnings Yield (Greenblatt) % is ranked higher than
56% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. Q: 2.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
Q' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.5  Med: 6.1 Max: 7.3
Current: 2.5
2.5
7.3

More Statistics

Revenue (TTM) (Mil) $6,878
EPS (TTM) $ 0.73
Beta0.76
Short Percentage of Float11.56%
52-Week Range $60.95 - 83.04
Shares Outstanding (Mil)235.92

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 8,143 8,515 8,895
EPS ($) 4.44 5.11 5.82
EPS without NRI ($) 4.44 5.11 5.82
EPS Growth Rate
(Future 3Y To 5Y Estimate)
14.03%
Dividends per Share ($)
» More Articles for NYSE:Q

Headlines

Articles On GuruFocus.com
The Big 3: Larry Robbins' Top 2nd-Quarter Buys Aug 16 2016 
Weekly 3-Year Low Highlight: TDC, Q, GRAM, XCO Dec 09 2013 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
AT&T Inc. (T) Dividend Stock Analysis Jan 27 2011 
Stocks Jim Simons Keeps on Buying: CL, Q, LMT, NVO, HRB Jan 25 2011 
CenturyLink, Inc. – A Qwest for Growth Nov 22 2010 
Which S&P 500 Company Has the Shakiest Dividend: AT&T, Pepco, Qwest, CenturyTel, Diamond Offshore May 17 2010 

More From Other Websites
QUINTILES IMS HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 24 2017
QuintilesIMS Announces Pricing of Senior Notes Feb 23 2017
QuintilesIMS Announces Pricing of Senior Notes Feb 23 2017
QUINTILES IMS HOLDINGS, INC. Financials Feb 22 2017
Quintiles IMS Incorporated -- Moody's rates Quintiles IMS's new Euro notes Ba3; Sr. Sec. term loans... Feb 22 2017
QUINTILES IMS HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 22 2017
QuintilesIMS Announces Offering of Senior Notes and Proposed Refinancing of Existing Indebtedness Feb 22 2017
QuintilesIMS Announces Offering of Senior Notes and Proposed Refinancing of Existing Indebtedness Feb 22 2017
Post Earnings Coverage as Agilent Revenue Gained 4%, Adjusted EPS Advanced 15% Feb 21 2017
QuintilesIMS upgraded by Wells Fargo Feb 17 2017
QUINTILES IMS HOLDINGS, INC. Files SEC form 10-K, Annual Report Feb 16 2017
Quintiles IMS Holdings, Inc. :Q-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 Feb 16 2017
QuintilesIMS Named to FORTUNE’s 2017 List of “World’s Most Admired Companies” Feb 16 2017
Quintiles IMS Holdings, Inc. :Q-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017 Feb 15 2017
QuintilesIMS releases first earnings report as a combined company Feb 14 2017
Edited Transcript of Q.N earnings conference call or presentation 14-Feb-17 2:00pm GMT Feb 14 2017
QUINTILES IMS HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 14 2017
QuintilesIMS Reports Fourth-Quarter and Full-Year 2016 Results, Issues First-Quarter and Full-Year... Feb 14 2017
LabCorp In Talks to Buy Contract Researcher PPD Feb 06 2017
Quintiles IMS Holdings, Inc. breached its 50 day moving average in a Bullish Manner : Q-US :... Feb 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)